We have assembled a team of world experts in cancer immunotherapy to develop therapies that target abnormal proteins called neoantigens, which are produced by cancer cells. Our programs are designed to leverage multiple facets of the immune response to elicit potent immune attack of tumors, with the aim of providing durable response to patients in need.
At Neon we are committed to advancing the field of cancer immunotherapy by investing in research in neoantigen biology, epitope prediction, cancer bioinformatics, personalized therapies and advanced immune profiling of cancer patients.
Headquartered in Cambridge, MA., Neon Therapeutics is a private company launched in 2015 with $55 million in Series A venture capital financing from Third Rock Ventures, Clal Biotechnology Industries and Access Industries.
Latest funding size
Time since last funding
|Access Industries, Wellington Management, Third Rock Ventures, Nextech Invest, Fidelity Management and Research Company, Clal Biotechnology Industries, Inbio Ventures, Partner Fund Management|